Cargando…
Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies
Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869882/ https://www.ncbi.nlm.nih.gov/pubmed/36742134 http://dx.doi.org/10.22038/IJBMS.2022.66890.14668 |
_version_ | 1784876861174579200 |
---|---|
author | Azimifar, Mohammad Amin Hashemi, Maryam Babaei, Nahid Salmasi, Zahra Doosti, Abbas |
author_facet | Azimifar, Mohammad Amin Hashemi, Maryam Babaei, Nahid Salmasi, Zahra Doosti, Abbas |
author_sort | Azimifar, Mohammad Amin |
collection | PubMed |
description | Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated therapeutics is still restricted by a class of potent immunoregulatory cytokines, systemic dose-limiting toxicities, ILs pleiotropy, and administration issues. During previous years, the area of transferring genes encoding immunostimulatory ILs was fundamentally widened to overcome these challenges and expedite ILs-based tumor regression. Numerous viral and non-viral delivery systems are currently available to act as crucial elements of the gene therapy toolbox. Moreover, cell-based cancer therapies are recruiting MSCs in the role of versatile gene delivery platforms to design one of the promising therapeutic approaches. These formulated gene carrier systems can provide possible alternatives to diminish dose-limiting adverse effects, promote administration, and enhance the therapeutic activity of ILs-derived treatment modalities in cancer treatment. This review provides a discussion on the advances of ILs gene delivery systems while focusing on the developing platforms in preclinical cancer immunogene therapy studies. |
format | Online Article Text |
id | pubmed-9869882 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Mashhad University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-98698822023-02-02 Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies Azimifar, Mohammad Amin Hashemi, Maryam Babaei, Nahid Salmasi, Zahra Doosti, Abbas Iran J Basic Med Sci Review Article Cytokine-mediated cancer therapy has the potential to enhance immunotherapeutic approaches and cancer elimination plans through the endowing of the immune system by providing improved anticancer immunity. Despite the encouraging pioneer studies on interleukins (ILs), the influence of ILs-originated therapeutics is still restricted by a class of potent immunoregulatory cytokines, systemic dose-limiting toxicities, ILs pleiotropy, and administration issues. During previous years, the area of transferring genes encoding immunostimulatory ILs was fundamentally widened to overcome these challenges and expedite ILs-based tumor regression. Numerous viral and non-viral delivery systems are currently available to act as crucial elements of the gene therapy toolbox. Moreover, cell-based cancer therapies are recruiting MSCs in the role of versatile gene delivery platforms to design one of the promising therapeutic approaches. These formulated gene carrier systems can provide possible alternatives to diminish dose-limiting adverse effects, promote administration, and enhance the therapeutic activity of ILs-derived treatment modalities in cancer treatment. This review provides a discussion on the advances of ILs gene delivery systems while focusing on the developing platforms in preclinical cancer immunogene therapy studies. Mashhad University of Medical Sciences 2023-02 /pmc/articles/PMC9869882/ /pubmed/36742134 http://dx.doi.org/10.22038/IJBMS.2022.66890.14668 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Azimifar, Mohammad Amin Hashemi, Maryam Babaei, Nahid Salmasi, Zahra Doosti, Abbas Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies |
title | Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies |
title_full | Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies |
title_fullStr | Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies |
title_full_unstemmed | Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies |
title_short | Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies |
title_sort | interleukin gene delivery for cancer gene therapy: in vitro and in vivo studies |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869882/ https://www.ncbi.nlm.nih.gov/pubmed/36742134 http://dx.doi.org/10.22038/IJBMS.2022.66890.14668 |
work_keys_str_mv | AT azimifarmohammadamin interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies AT hashemimaryam interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies AT babaeinahid interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies AT salmasizahra interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies AT doostiabbas interleukingenedeliveryforcancergenetherapyinvitroandinvivostudies |